Dr. Robert Wills is the Chairman of Cymabay Therapeutics’ Board of Directors since October 2015 and has been a member of the Board since March, 2015.

Dr. Wills has more than 35 years of experience in the pharmaceutical industry and spent over 25 years at Johnson & Johnson, where he held positions as Senior Vice President of Global Development, Vice President of Alliance Management and member of the R&D Board of Directors. He has been responsible for the R&D pipeline and for managing strategic alliances for the Pharmaceutical Group worldwide, playing an active role in the negotiations of these alliances. Dr. Wills also served on several of the Company Boards and key decision-making committees. He began his career at Hoffmann-LaRoche where he spent 10 years in several roles of scientific responsibility.

Dr. Wills holds a B.S. in Biochemistry and an M.S. in Pharmaceutics from the University of Wisconsin, and a Ph.D. in Pharmaceutics from the University of Texas.

Dr. Iain D. Dukes is a Venture Partner at OrbiMed Advisors.

Dr. Dukes previously served as Senior Vice-President and Head of business development and licensing for Merck Research Laboratories. Prior to joining Merck, Dr. Dukes was Vice President of External Research and Development at Amgen. Dr. Dukes has also served as President and CEO, and a member of the Board of Directors, of Essentialis Therapeutics, a clinical-stage biotechnology company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases.

Previously, Dr. Dukes was Vice-President of Scientific and Technology licensing at GlaxoSmithKline, and prior to that, he held various positions at Glaxo Wellcome, including head of exploratory development for metabolic and urogenital diseases and head of the Ion Channel Drug Discovery Group. Dr. Dukes is Chaiman of Iovance Biotherapeutics (NASQ: IOVA) and serves on the Board of Directors of Themis Biosciences (acquired by Merck & Co), Ikena Oncology, KaNDy Therapeutics (previously as Chairman, acquired by Bayer AG), NeRRe Therapeutics, ReViral Limited, and ENYO Therapeutics. Dr. Dukes co-founded and is Chief Executive Officer of Theseus Pharmaceuticals; co-founded and serves on the Board of Directors of Kartos Therapeutics where he is President; and co-founded Telios Pharma, where he is President and serves on the Board of Directors. He is also Executive Chairman of Angiex.

Dr. Dukes holds an M.A. and D.Phil, from the University of Oxford, an MSc. in Cardiovascular Studies from the University of Leeds, and a B.Sc. in Pharmacology from the University of Bath.

Mr. Truex serves as CEO and Chairman for Thryv Therapeutics (Formerly LQT Therapeutics).

Before Thryv Therapeutics, Mr. Truex recently served as the Executive Chairman, Director, and Chief Executive Officer of Anthera Pharmaceuticals.

Mr. Truex has been involved in over $5 billion in biotech financing and strategic transactions. His recent experience includes initial public offerings for Milestone (Board Member, 2019), Trius (Board Member, 2010), Anthera (CEO, 2010), Peninsula (CEO, 2004), and Versicor (Vice President, 2000). Mr. Truex was Founder, President, and CEO of Peninsula Pharmaceuticals which was acquired by Johnson & Johnson and Forest for more than $700 million.

Mr. Truex began his biotech career at Eli Lilly where his business development experience included the Lilly ICOS joint venture for the development of Cialis®. Mr. Truex is a member of the Board of Milestone (MIST), Cymabay (CBAY), Anthera (ANTH), and Gladius.

Mr. Truex obtained his MBA from Indiana University and a BA in Economics from the University of Waterloo.

Dr. David J. Mazzo is the President and Chief Executive Officer at Lisata Therapeutics (previously Caladrius Biosciences).

Dr. Mazzo is a pharmaceutical executive and strategic leader with more than 35 years of broad international experience developing and launching drug products for both big pharma and emerging pharma in the U.S., Canada, Europe and Japan. He is also a seasoned board director, having served on the boards of all the companies for which he was CEO, as well as Essex Chemie AG (EU subsidiary of Schering-Plough), Avanir Pharmaceuticals and EyePoint Pharmaceuticals, where he served as chairman of the board until 2018. Dr. Mazzo is the current chairman of the board of Visioneering Technologies, Inc.

Dr. Mazzo earned a Ph.D. in Analytical Chemistry and an M.S. in Chemistry from the University of Massachusetts (Amherst), and he completed a research fellowship at the École Polytechnique Fédérale de Lausanne (Switzerland). He also holds a B.S. (Chemistry) and a B.A. (Honors – Interdisciplinary Humanities) from Villanova University (Pennsylvania).

Dr. François-Thomas Michaud serves as the Chief Executive Officer at Feldan Therapeutics and is a co-founder of the company.

Dr. Michaud co-founded and became CEO of Feldan in 2007 while completing his PhD degree in chemical engineering. At the time, the company was mainly active in the production and international distribution of bioreagents. In parallel with sales activities, Dr. Michaud and Feldan’s team worked on a research project that led to the inception of proprietary cell-penetrating technology: the Feldan Shuttle. Over the years, Dr. Michaud’s value-creating vision has shaped the business model of the company, which now focuses exclusively on therapeutic development.

Dr. Michaud is actively engaged in corporate, academic, and entrepreneurial communities of the Province of Quebec and Canada as an administrator, speaker, and mentor. He is also a board member of Bio-Québec, Ag Biocentre and Entrepreneurial Laval.

Dr. HoWon Joseph Kim serves as GC Cell's Chief Technology Officer and Internal Director.

He is overseeing the company's research and development. Dr. Kim graduated from the College of Pharmacy, Seoul National University, and completed his master's degree in immunology at the same university before earning his Ph.D. in biochemistry at the School of Medicine, UCLA. Since then, he has led cell therapy research at global biotech companies such as Stemgent, ORIG3N, and STEMCELL Technologies. Most recently, he was co-founder and Chief Scientific Officer of K2B Therapeutics, a Boston-based biotechnology company, where he led the development of anti-cancer drugs.

Gladys Nunez, Director Amgen Ventures, joined Amgen in 1997 and leads investment diligence for corporate ventures including the Amgen Ventures R&D Seed Fund. As part of her portfolio management activities, she is a board observer on Obsidian Therapeutics, Inversago, Kernal Bio, Caraway Therapeutics, Celsius, and Ribometrix. Based in Amgen’s Cambridge, Ma site she is a member of the external outreach team supporting local outreach/incubator activities, and a member of the cross-site leadership team.

Prior to joining Amgen Ventures in 2014, Ms Nunez spent 12 years in Amgen's Business Development group prospecting and negotiating external alliances. Prior to joining Amgen’s Business Development organization, Ms Nunez worked 7 years in R&D, concurrent between Amgen and AstraZeneca. She holds an MSc in Biochemical Pharmacology from the University of Southampton in England, and BSc from Marist College in Pre-Med.

As an active member of the Mass Bio community, Ms Nunez is a board member and treasurer of Latinos in Bio, a non-profit sponsored by Mass Bio to increase the role of Latinos in the life sciences including career development, education and healthcare disparities. She is also a member of Women in Bio supporting women’s entrepreneurial development and increasing presence of women in venture capital careers.